A randomized, placebo-controlled, double-blinded pilot study using carvedilol-CR as a p-glycoprotein inhibitor as adjunct therapy in the treatment of medically-refractory epilepsy.
Phase of Trial: Phase II/III
Latest Information Update: 24 Apr 2016
At a glance
- Drugs Carvedilol (Primary)
- Indications Epilepsy
- Focus Therapeutic Use
- 13 Apr 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov
- 25 Apr 2011 Planned end date changed from 1 Dec 2010 to 1 Apr 2011 as reported by ClinicalTrials.gov.
- 25 Apr 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.